Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinji Kagami

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|March 5, 2011
[IL-23 and Th17 cells in infections and psoriasis]Shinji Kagami
The Journal of Dermatology|July 28, 2018
Oral propranolol for infantile hemangiomas beyond the proliferative phaseShinji Kagami, Tatsuo Katori
The Journal of Dermatology|April 1, 2018
Thirty-two Japanese cases of infantile hemangiomas treated with oral propranololShinji Kagami, Masahide Kaneko, Tatsuo Katori
Journal of Cosmetic Dermatology|July 5, 2020
Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areataShinji Kagami, Yuriko Kishi, Haruko Hino
The Journal of Dermatology|June 29, 2018
Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatmentShinji Kagami, Masahide Kaneko, Akiko Kishi, et al.
The Journal of Dermatology|March 25, 2006
A probable case of Muckle-Wells syndromeShinji Kagami, Hidehisa Saeki, Yoshihiro Kuwano, et al.
The Journal of Investigative Dermatology|December 25, 2009
Circulating Th17, Th22, and Th1 cells are increased in psoriasisShinji Kagami, Heather L Rizzo, Jennifer J Lee, et al.
Journal of Glaucoma|February 6, 2019
Long-term Side Effects Including Blepharitis Leading to Discontinuation of RipasudilHitomi Saito, Shinji Kagami, Koichi Mishima, et al.
The Journal of Investigative Dermatology|August 25, 2005
Mechanism of thymus- and activation-regulated chemokine (TARC)/CCL17 production and its modulation by roxithromycinMayumi Komine, Takashi Kakinuma, Shinji Kagami, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 6, 2010
IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicansShinji Kagami, Heather L Rizzo, Stephen E Kurtz, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|March 5, 2011
[IL-23 and Th17 cells in infections and psoriasis]Shinji Kagami
The Journal of Dermatology|July 28, 2018
Oral propranolol for infantile hemangiomas beyond the proliferative phaseShinji Kagami, Tatsuo Katori
The Journal of Dermatology|April 1, 2018
Thirty-two Japanese cases of infantile hemangiomas treated with oral propranololShinji Kagami, Masahide Kaneko, Tatsuo Katori
Journal of Cosmetic Dermatology|July 5, 2020
Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areataShinji Kagami, Yuriko Kishi, Haruko Hino
The Journal of Dermatology|June 29, 2018
Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatmentShinji Kagami, Masahide Kaneko, Akiko Kishi, et al.
The Journal of Dermatology|March 25, 2006
A probable case of Muckle-Wells syndromeShinji Kagami, Hidehisa Saeki, Yoshihiro Kuwano, et al.
The Journal of Investigative Dermatology|December 25, 2009
Circulating Th17, Th22, and Th1 cells are increased in psoriasisShinji Kagami, Heather L Rizzo, Jennifer J Lee, et al.
Journal of Glaucoma|February 6, 2019
Long-term Side Effects Including Blepharitis Leading to Discontinuation of RipasudilHitomi Saito, Shinji Kagami, Koichi Mishima, et al.
The Journal of Investigative Dermatology|August 25, 2005
Mechanism of thymus- and activation-regulated chemokine (TARC)/CCL17 production and its modulation by roxithromycinMayumi Komine, Takashi Kakinuma, Shinji Kagami, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 6, 2010
IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicansShinji Kagami, Heather L Rizzo, Stephen E Kurtz, et al.
Pageof 4